Tuesday, April 29th, 2025

Mapletree Logistics Trust (MLT SP): Navigating Trade Tensions – BUY Rating


Maybank Research Pte Ltd

April 25, 2025

Mapletree Logistics Trust: Navigating Trade Tensions with a Cautious Outlook

Mapletree Logistics Trust (MLT SP) faces headwinds from falling distributions and trade tensions, but its reasonable valuation merits a BUY rating.

Key Takeaways from MLT’s 4QFY24/25 Performance

  • MLT reported a 4QFY24/25 distribution per unit (DPU) of SGD1.955 cents, marking a decrease of 2.4% quarter-over-quarter and 11.6% year-over-year [[1]].
  • The full-year DPU stood at SGD8.053 cents, a 10.6% decrease compared to the previous year [[1]].
  • Higher borrowing costs, weakness in China, and reduced divestment gains impacted the distribution [[1]].
  • Portfolio occupancy remained stable, and rental reversions were positive, excluding China [[1]].
  • Gearing saw a slight increase, while debt cost and coverage ratios remained stable [[1]].

Financial Performance Analysis

MLT’s financial results reflect both resilience and challenges in the current economic climate [[1]].

  • 4Q revenue was SGD179.6 million, down 1.5% QoQ and 0.8% YoY [[1]].
  • Net property income (NPI) for 4Q was SGD152.8 million, a decrease of 2.8% QoQ and 1.6% YoY [[1]].
  • Full-year revenue reached SGD727 million, and NPI was SGD625.3 million, representing declines of 0.9% and 1.5% YoY, respectively [[1]].
  • Weakness in China, portfolio reconstitution, FX volatility, and lower margins influenced the results [[1]].
  • Borrowing costs increased YoY due to repricing but decreased QoQ, benefiting from lower interest rates on unhedged loans [[1]].

The decline in DPU was primarily due to lower distribution of divestment gains [[1]]. Portfolio occupancy remained strong at 96.2% [[1]]. Gains in Japan and China offset declines in Singapore, Malaysia, and Vietnam [[1]]. Management indicated that 85% of group revenue comes from tenants serving domestic consumption, though export-oriented economies like Singapore and Vietnam experienced impacts from warehousing pulled-back orders [[1]]. Rent reversion was +5.1% (+6.9% ex-China) for 4Q, compared to +3.4% (+5.4% ex-China) for 3Q [[1]]. China’s reversion was less negative at -9.4% compared to -10.2% [[1]]. Focus remains on tenant retention due to substantial revenue from China due for renewal this FY [[1]].

Capital Management and Portfolio Valuation

MLT maintains a prudent approach to capital management [[1]].

  • Gearing stood at 40.7% (up from 40.3% in 3Q), with a stable debt cost of 2.7% and a coverage ratio of 2.9x [[1]].
  • Portfolio valuation remained stable due to capital expenditure and M&As, offset by FX translation losses and fair value losses in Singapore, Hong Kong, China, and South Korea due to higher cap rates [[2]].
  • Macro uncertainties and regional trade evolution may influence the pace of capital recycling [[2]].

Revised Target Price and Recommendation

Despite a cautious outlook, Maybank retains a BUY recommendation [[2]].

  • DPU estimate lowered by 3.7% for FY25/26 due to the absence of divestment gains [[2]].
  • The DDM-based target price is trimmed to SGD1.30 from SGD1.35 [[2]].
  • The BUY recommendation is maintained based on a reasonable valuation with a 6% yield and 0.9x PB [[2]].

Key Statistics

  • Share Price: SGD 1.16 [[2]]
  • 12m Price Target: SGD 1.30 (+16%) [[2]]
  • Previous Price Target: SGD 1.35 [[2]]
  • 52w high/low (SGD): 1.49/1.05 [[2]]
  • 3m avg turnover (USDm): 74.2 [[2]]
  • Free float (%): na [[2]]
  • Issued shares (m): 4,994 [[2]]
  • Market capitalisation: SGD5.8B/USD4.4B [[2]]
  • Major shareholders: Temasek Holdings Pte Ltd. (Investment Co 25.8%) [[2]]

Financial Table

FYE Mar (SGD m) FY24A FY25A FY26E FY27E FY28E
Revenue 734 727 718 729 740
Net property income 635 625 621 631 640
Core net profit 447 406 357 370 378
Core EPU (cts) 6.8 6.2 5.5 5.6 5.6
Core EPU growth (%) 0.4 (8.0) (12.3) 2.4 1.0
DPU (cts) 9.0 8.1 7.0 7.1 7.2
DPU growth (%) (0.1) (10.6) (13.1) 2.1 0.8
P/NTA (x) 1.1 1.0 0.9 0.9 0.9
DPU yield (%) 6.2 6.1 6.0 6.2 6.2
ROAE (%) 4.9 4.6 4.2 4.3 4.3
ROAA (%) 3.3 2.9 2.6 2.6 2.7
Debt/Assets (x) 0.38 0.40 0.40 0.40 0.39
Consensus DPU 8.0 8.0 7.7
MIBG vs. Consensus (%) (12.5) (10.7) (5.8)

Risks to Consider

Several factors could impact MLT’s performance [[3]]:

  • Slower growth in China
  • Escalating trade tensions
  • Slower pace of capital recycling
  • Higher interest rates
  • FX translation losses

Value Proposition

MLT is the second-largest industrial sector S-REIT, backed by sponsor Mapletree Investments (Temasek Holdings) [[4]]. Its portfolio has grown significantly since its IPO in 2005, diversifying across nine Asian geographies [[4]]. MLT focuses on capital recycling and redevelopment, aiming to enhance NAV growth [[4]].

Price Drivers and Historical Share Price Trends

Key events have influenced MLT’s share price [[4]]:

  • Jan-20: Acquisition of Kobe Logistics Centre [[4]].
  • Oct-20: Acquisition of nine assets in China, Malaysia, and Vietnam [[4]].
  • Nov-21: Acquisition of warehouses in China, Vietnam, and Japan [[4]].
  • Mar-23: Non-redemption of SGD180m perp, acquisition of warehouses in Japan, Sydney, and Korea [[4]].
  • 2024: Acquisitions in Malaysia, India, and Vietnam, divestment of SGD237m, and change of CEO [[4]].

Financial Metrics and Swing Factors

Capital recycling, divestment gains, and currency appreciation support distribution [[4]]. NPI margins are expected to stabilize, with a well-staggered lease expiry profile [[4]]. Upside factors include improved leasing demand and rental reversion, while downside risks include economic slowdown, lease terminations, FX volatility, and rising interest rates [[4]].

ESG Assessment

MLT’s ESG profile reveals several key considerations [[5]]:

  • Business Model & Industry Issues: Susceptible to sustainability-focused investors due to its need for additional capital. Regulated by MAS under Singapore’s code on collective investment schemes [[5]].
  • Material E issues: Focus on energy intensity reduction and renewable energy. Secured SGD800m of green funding [[5]].
  • Key G metrics and issues: Externally managed by a subsidiary of Mapletree Investments. Board comprises 12 directors, with 7 independent and 4 females [[5]].
  • Material S issues: Aligned initiatives to sponsor’s CSR framework. High gender diversity [[5]].

Financial Statement Summary

Key figures from the financial statements [[6]]:

  • Revenue: FY24A: 733.9, FY25A: 727.0, FY26E: 718.3, FY27E: 729.1, FY28E: 740.0
  • Net Property Income: FY24A: 634.9, FY25A: 625.3, FY26E: 621.3, FY27E: 630.7, FY28E: 640.1
  • Core Net Profit: FY24A: 447.1, FY25A: 406.4, FY26E: 357.1, FY27E: 369.6, FY28E: 377.9
  • Distributable Income to Unitholders: FY24A: 447.1, FY25A: 406.4, FY26E: 357.1, FY27E: 369.6, FY28E: 377.9

Key Ratios Analysis

Key ratios provide insights into MLT’s performance and financial health [[7]]:

  • Revenue Growth: FY24A: 0.4, FY25A: (0.9), FY26E: (1.2), FY27E: 1.5, FY28E: 1.5
  • Net Property Income Growth: FY24A: 0.0, FY25A: (1.5), FY26E: (0.6), FY27E: 1.5, FY28E: 1.5
  • Core Net Profit Growth: FY24A: 3.3, FY25A: (9.1), FY26E: (12.1), FY27E: 3.5, FY28E: 2.2
  • Net Gearing (%): FY24A: 66.9, FY25A: 72.9, FY26E: 71.6, FY27E: 70.2, FY28E: 68.9


True Corporation’s Core Profit Surges 295% in 3Q24 Amid Strong Cost Controls and ARPU Growth

Date of Report: October 15, 2024Broker: UOB Kay Hian Company Overview True Corporation (TRUE) was established from an amalgamation between True Corporation and Total Access Communication (DTAC) as a telecommunication services provider. It operates...

BRC Asia Reports Record Profit: Attractive 8.4% Dividend Yield Despite Industry Headwinds

In-Depth Analysis of Market Trends and Company Performances In-Depth Analysis of Market Trends and Company Performances Broker Name: Lim & Tan Securities Date of Report: 22 November 2024 Overview of Financial Markets In the...

Sino Biopharmaceutical Ltd Positioned for Strong Gains with Technical Buy Momentum

Date: September 17, 2024Broker: CGS-CIMB Securities Company Overview Sino Biopharmaceutical Ltd (Stock Code: 1177) is a major pharmaceutical company based in Hong Kong. It focuses on the research, development, production, and distribution of biopharmaceutical...